ˆøŠÔŒ¤‹†Žº
















2024”N
1. ˆøŠÔ’mL
"”畆\‘¢‚Æ–ò•¨‚̔畆‹zŽû"
AIR Cafe#005u”§‚Æ”¯`…‚Ì‹êŠv, 2024”N5ŒŽ30“ú.

2023”N
6. îà–Ø—I¬, •ˆä‰hŒ›, “V–ìØ“E, ˆøŠÔ’mL, ˆÉ“¡‚œA, ‘ºã’¼, ’֍_’‰, ¼”ö³º, Œ´³Æ, “c‘ãN“T, ‹S–Ø‹ªŒº
"—n‰ðŒ^ƒ}ƒCƒNƒƒj[ƒhƒ‹ƒAƒŒƒC‚̐¬Œ`"
2023”N“x¸–§HŠw‰ïH‹G‘å‰ïŠwpu‰‰‰ï, 2023”N9ŒŽ14“ú.
5. ”–“cˆç”ü, ˆøŠÔ’mL
"ƒiƒCƒAƒVƒ“ƒAƒ~ƒh‚̈À’萫‹y‚є畆“§‰ß«•]‰¿"
‘æ39‰ñ“ú–{DDSŠw‰ïŠwpW‰ï, 2023”N7ŒŽ28“ú.
4. ’|‰º^—R, ¬ŸºˆÇ”T, ˆäãT‰î, •½–ì–¾—Ç, dXNŽi, ˆøŠÔ’mL
"ƒiƒm…‚É‚æ‚ée…«‰»‡•¨‚̔畆“§‰ß‹““®‚ÆŠp‘wŠÜ…—ʂւ̉e‹¿"
‘æ39‰ñ“ú–{DDSŠw‰ïŠwpW‰ï, 2023”N7ŒŽ27“ú.
3. ‘å’J‘‹I, ˆøŠÔ’mL
"Ž‰—n«–ò•¨‚̔畆“§‰ß«‚¨‚æ‚є畆‘Ø—¯«‚ÉŠÖ‚·‚錟“¢"
‘æ39‰ñ“ú–{DDSŠw‰ïŠwpW‰ï, 2023”N7ŒŽ27“ú.
2. ‹àŠÛ‹Mr, —L“cV•½, “‡‘º‰À‹v, Šâ£—zˆê˜Y, ˆøŠÔ’mL
"“dê‚ð—p‚¢‚½‚•ªŽqˆã–ò•i‚ÌŠá“à–ò•¨‘—’B‘£i"
“ú–{–òŠw‰ï‘æ143”N‰ï, 2023”N3ŒŽ26“ú.
1. ‘³–{ØX”ü, ˆäãˆŸ¹Žq, ²“¡G», ˆøŠÔ’mL
"–û’†ƒiƒm—±Žq•ªŽU‘Ì‚É•ïŠÜ‚µ‚½e…«‚•ªŽq‰»‡•¨‚̔畆“§‰ß‘£i‚ÉŠÖ‚·‚錤‹†"
“ú–{–òŠw‰ï‘æ143”N‰ï, 2023”N3ŒŽ26“ú.

2022”N
1. H. Takei, S. Matsushima, K. Kawabata, T. Ito, R. Mizuguchi, T. Hikima, H. Tsubaki, M. Hara, Y. Tashiro, T. Oniki, M. Matsuo
"New shape coated microneedle array for medical application"
The 19th International Conference on Precision Engineering, November 28-December 1, 2022.

2021”N
4. ì’[ˆê‹P, ¼“‡r–ç, …Œû—½, ˆÉ“¡‚œA, ˆøŠÔ’mL, ‘ºã’¼, ¼”ö³º, “c‘ãN“T, Œ´³Æ, ’֍_’‰
"ˆã—×pƒ}ƒCƒNƒƒj[ƒhƒ‹‚ÌŒ¤‹†"
2021”N“x¸–§HŠw‰ïH‹G‘å‰ïŠwpu‰‰‰ï, 2021”N9ŒŽ23“ú.
3. …Œû—½, …–ì—LŠó, ŽR“cˆê–ç, ¼“‡r–ç, “c‘ãN“T, ¼”ö³º, ˆÉ“¡‚œA, ˆøŠÔ’mL
"‰GŒûŒ^ƒ}ƒCƒNƒƒj[ƒhƒ‹‚̃j[ƒhƒ‹–{”‚É‚æ‚éŒo”ç–ò•¨‘—’B‘£i‚ւ̉e‹¿‚ÉŠÖ‚·‚錤‹†"
‘æ37‰ñ“ú–{DDSŠw‰ïŠwpW‰ï, 2021”N6ŒŽ29-30“ú.
2. ‘³–{ØX”ü, ˆäãˆŸ¹Žq, ²“¡G», ˆøŠÔ’mL
"–û’†ƒiƒm—±Žq•ªŽU‘Ì‚É‚æ‚ée…«‚•ªŽq‚̔畆“§‰ß‘£iƒƒJƒjƒYƒ€‚̉ð–¾"
‘æ37‰ñ“ú–{DDSŠw‰ïŠwpW‰ï, 2021”N6ŒŽ29-30“ú.
1. Junsaku KITAGAWA, Hayato ARAI, Hiroyuki IIDA, Jiro MUKAI, Kenji FURUKAWA, Seitaro OHTSU, Susumu NAKADE, Tomohiro HIKIMA, Miwa HARANAKA, Naoto UEMURA
"A Phase I study to evaluate safety, tolerability and pharmacokinetics of high doses of camostat mesylate in healthy subjects provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19"
ASCPT (American Society for Clinical Pharmacology & Therapeutics) 2021 Annual Meeting, March 12, 2021.





‚±‚̃y[ƒW‚ÉŠÖ‚·‚鎿–â‚Í‚Ü‚Å